Crohn Disease — An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
Citation(s)
A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease